Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 5,02 M
EBIT 2016 -22,8 M
Net income 2016 -24,1 M
Debt 2016 8,56 M
Yield 2016 -
Sales 2017 3,00 M
EBIT 2017 -25,0 M
Net income 2017 -25,0 M
Debt 2017 18,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 28,1x
EV / Sales 2017 50,2x
Capitalization 133 M
More Financials
Company
Onxeo SA engages in the development of drugs for the treatment of cancer.The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AMEP.It also offers specialty products under the brand names Loramyc/Oravig, Sitavig, and Fluriad.The company was... 
Sector
Pharmaceuticals
Calendar
06/07Presentation
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
05/02 PUBLICATION OF 2015 REFERENCE DOCUME : Offentliggørelse af Reference Document fo..
04/28 ONXEO : First Quarter 2016 Financial information and Business Update
04/06 ONXEO : Passing on Onxeo’s Extraordinary and Ordinary General Meeting // D..
04/05 ONXEO : announces positive DSMB recommendation to continue Livatag ReLive study ..
03/26 ONXEO : Announces Closing of DNA Therapeutics Acquisition
03/25 ONXEO ANNOUNCES CLOSING OF DNA THERA : gennemfører opkøbet af DNA Therapeutics (..
03/23 ONXEO ANNOUNCES ESTABLISHMENT OF U S : etablerer amerikansk datterselskab (Onxeo..
03/21 ONXEO : Announces Establishment of U.S. Subsidiary
More news
Sector news : Pharmaceuticals - NEC
08:49aDJBAYER : Room to Increase Monsanto Bid Is Limited -- WSJ
08:49aDJSANOFI : Moves to Replace Medivation's Board -- WSJ
04:36a CHUGAI PHARMACEUTICAL : Bispecific Antibody “ACE910/Emicizumab” Phas..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions